Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.
deep vein thrombosis
fibrinolysis
obesity
plasminogen activator inhibitor 1
pulmonary embolism
venous thromboembolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
08
11
2021
accepted:
07
03
2022
pubmed:
16
3
2022
medline:
29
6
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
Plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated with VTE remains uncertain. To investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity. A population-based nested case-control study, comprising 383 VTE cases and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort. PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across PAI-1 tertiles. The VTE risk increased dose-dependently across PAI-1 tertiles (P for trend <.001) in the age- and sex-adjusted model. The OR of VTE for the highest versus lowest tertile was 1.73 (95% CI 1.27-2.35), and risk estimates were only slightly attenuated with additional stepwise adjustment for body mass index (BMI; OR 1.59, 95% CI 1.16-2.17) and C-reactive protein (CRP; OR 1.54, 95% CI 1.13-2.11). Similar results were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. In obese subjects (BMI of ≥30 kg/m Our findings indicate that plasma PAI-1 is associated with increased risk of future incident VTE and has the potential to partially mediate the VTE risk in obesity.
Sections du résumé
BACKGROUND
Plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated with VTE remains uncertain.
OBJECTIVE
To investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity.
METHODS
A population-based nested case-control study, comprising 383 VTE cases and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort. PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE across PAI-1 tertiles.
RESULTS
The VTE risk increased dose-dependently across PAI-1 tertiles (P for trend <.001) in the age- and sex-adjusted model. The OR of VTE for the highest versus lowest tertile was 1.73 (95% CI 1.27-2.35), and risk estimates were only slightly attenuated with additional stepwise adjustment for body mass index (BMI; OR 1.59, 95% CI 1.16-2.17) and C-reactive protein (CRP; OR 1.54, 95% CI 1.13-2.11). Similar results were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. In obese subjects (BMI of ≥30 kg/m
CONCLUSION
Our findings indicate that plasma PAI-1 is associated with increased risk of future incident VTE and has the potential to partially mediate the VTE risk in obesity.
Identifiants
pubmed: 35289062
doi: 10.1111/jth.15701
pmc: PMC9314992
pii: S1538-7836(22)01910-9
doi:
Substances chimiques
Plasminogen Activator Inhibitor 1
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1618-1626Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
Références
Thromb Res. 2020 Aug;192:64-72
pubmed: 32454303
Semin Thromb Hemost. 2013 Jul;39(5):533-40
pubmed: 23625755
J Thromb Haemost. 2021 Aug;19(8):2019-2028
pubmed: 33876560
Diabetes. 1997 May;46(5):860-7
pubmed: 9133556
Hypertension. 2002 Dec;40(6):859-65
pubmed: 12468570
J Thromb Haemost. 2016 Aug;14(8):1561-71
pubmed: 27208592
Blood. 2019 Nov 7;134(19):1645-1657
pubmed: 31420334
Diab Vasc Dis Res. 2019 Sep;16(5):478-482
pubmed: 31064214
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Diabetes Care. 2002 Dec;25(12):2123-8
pubmed: 12453948
Semin Thromb Hemost. 2009 Feb;35(1):119-26
pubmed: 19308900
Am J Epidemiol. 2010 May 15;171(10):1109-15
pubmed: 20418276
Front Cardiovasc Med. 2021 Apr 16;8:653655
pubmed: 33937363
Blood Coagul Fibrinolysis. 2002 Oct;13(7):577-81
pubmed: 12439142
Metabolism. 2000 May;49(5):666-71
pubmed: 10831181
Obes Rev. 2002 May;3(2):85-101
pubmed: 12120424
J Thromb Haemost. 2022 Jul;20(7):1618-1626
pubmed: 35289062
Hypertens Res. 2011 Dec;34(12):1321-6
pubmed: 21814211
Thromb Res. 1991 Apr;62(1-2):55-64
pubmed: 1853306
J Thromb Haemost. 2019 Oct;17(10):1661-1669
pubmed: 31220397
Blood Rev. 2016 Nov;30(6):421-429
pubmed: 27233154
J Thromb Haemost. 2014 Dec;12(12):1993-2001
pubmed: 25292154
Thromb Haemost. 2017 Jan 26;117(2):390-400
pubmed: 27975103
Blood. 2010 Jul 8;116(1):113-21
pubmed: 20385790
Thromb Haemost. 2022 Apr;122(4):560-569
pubmed: 34264516
Nat Med. 1996 Jul;2(7):800-3
pubmed: 8673927
Thromb Res. 2014 Nov;134(5):1097-102
pubmed: 25193405
J Thromb Haemost. 2019 Jun;17(6):934-943
pubmed: 30920726
J Diabetes Complications. 2006 Jan-Feb;20(1):14-20
pubmed: 16389162
Eur Heart J. 2020 Jan 7;41(2):221-226
pubmed: 31195408
J Clin Epidemiol. 2003 Jun;56(6):598-603
pubmed: 12873656
J Clin Invest. 1996 Jan 1;97(1):37-46
pubmed: 8550848
Biochem Biophys Res Commun. 2010 Jan 29;392(1):47-52
pubmed: 20051227
Int J Obes Relat Metab Disord. 2004 Nov;28(11):1357-64
pubmed: 15356668
Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):173-8
pubmed: 11788479
Circ Genom Precis Med. 2018 Jan;11(1):e001956
pubmed: 29874180
Thromb Res. 2008;122(2):271-81
pubmed: 18508114
Nat Genet. 2019 Nov;51(11):1574-1579
pubmed: 31676865
Int J Epidemiol. 2012 Aug;41(4):961-7
pubmed: 21422063
Circulation. 1992 May;85(5):1822-7
pubmed: 1572039
J Intern Med. 2015 May;277(5):573-84
pubmed: 25161014
Am J Epidemiol. 1999 Aug 15;150(4):341-53
pubmed: 10453810
J Am Heart Assoc. 2017 May 26;6(6):
pubmed: 28550093
Clin Chim Acta. 2019 Apr;491:52-58
pubmed: 30659821
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Curr Drug Targets. 2019;20(16):1695-1701
pubmed: 31309890
Thromb Haemost. 2005 Apr;93(4):631-40
pubmed: 15841306
Thromb J. 2018 Jun 05;16:12
pubmed: 29991926
J Thromb Haemost. 2007 Apr;5(4):692-9
pubmed: 17367492
Am Heart J. 1992 Oct;124(4):854-60
pubmed: 1529901
Blood. 2012 Dec 6;120(24):4873-81
pubmed: 22990020
Circ Cardiovasc Genet. 2017 Apr;10(2):
pubmed: 28373160
Thromb Res. 2021 Jan;197:1-7
pubmed: 33157491
J Thromb Haemost. 2007 Jul;5(7):1462-8
pubmed: 17425664
Horm Metab Res. 2001 Oct;33(10):602-7
pubmed: 11607880
Front Cardiovasc Med. 2020 Dec 22;7:622473
pubmed: 33415130